维普中文期刊产品整合服务

Membrane-camouflaged supramolecular nanoparticles for co-delivery of chemotherapeutic and molecular-targeted drugs with siRNA against patient-derived pancreatic carcinoma

查看全文 作　　者：Honglin [1,2]Tang;Yanan [1,2]Xue;Bowen [2]Li;Xiaojie [2]Xu;Fu [1,3]Zhang;Jiajing [2]Guo;Qijun [1]Li;Tingting [2]Yuan;Yuan [2]Chen;Yubin [1]Pan;Yuan [2]Ping;Da [1]Li 高影响力作者 机构地区：[1]Department of Medical Oncology,Sir Run Run Shaw Hospital,School of Medicine,Zhejiang University,Hangzhou 310058,China;[2]College of Pharmaceutical Sciences,Zhejiang University,Hangzhou 310058,China;[3]Department of Hepatobiliary and Pancreatic Surgery,the First Affiliated Hospital,Zhejiang University,Hangzhou 310003,China高影响力机构 出　　处：《Acta Pharmaceutica Sinica B》索引2022年第12卷第8期,共17页高影响力期刊 基　　金：the National Key Research and Development Program of China (No.2018YFA0901800);Natural Science Foundation of Zhejiang Province (Distinguished Young Scholar Program,No.LR21H300002,China);National Natural Science Foundation of China (Nos.81573003 and 32000992);Chinese Society of Clinical Oncology (CSCO) oncology research foundation (Nos.Y-XD2019-243 and Y-Roche2019/2-0042);Joint Foundation of Zhejiang Natural Science FoundationZhejiang Society for Mathematical Medicine (LSY19H160005,China);the Chinese Postdoctoral Science Foundation (2018M642469);Scientific Research Fund of Zhejiang Provincial Education Department (Y202148347,China)。 摘　　要：Pancreatic cancer remains one of the most lethal malignancies worldwide. The combination of the first-line standard agent gemcitabine(GEM) with the molecular-targeted drug erlotinib(Er) has emerged as a promising strategy for pancreatic cancer treatment. However, the clinical benefit from this combination is still far from satisfactory due to the unfavorable drug antagonism and the fibrotic tumor microenvironment. Herein, we propose a membrane-camouflaged dual stimuliresponsive delivery system for the co-delivery of GEM and Er into pancreatic cancer cells and tissues to block the antagonism, as well as reshapes profibrotic tumor microenvironment via simultaneous delivery of small interference RNA(siRNA) for synergistic pancreatic cancer treatment. This “all-in-one”delivery system exhibits sensitive GSH and pH-dependent drug release profiles and enhances the inhibitory effects on the proliferation and migration of tumor cells in vitro. Excitingly, the systemic injection of such a biomimetic drug co-delivery system not only resulted in superior inhibitory effects against orthotopic pancreatic tumor and patient-derived tumor(PDX), but also greatly extended the survival rate of tumor-bearing mice. Our findings provide a promising therapeutic strategy against pancreatic cancer through the enhanced synergistic effect of target therapy, chemotherapy and anti-fibrotic therapy, which represents an appealing way for pancreatic cancer treatment. 关 键 词：Chemotherapy Target therapy SIRNA NANOMEDICINE Hybrid membrane Drug antagonism Pancreatic carcinoma Patient-derived tumor
相关文献

参考文献(52)

耦合文献(20)

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费